Holen Sie sich die Stockscreener-App
96.22
0.09%
-0.09
Handel nachbörslich:
98.14
1.92
+2.00%
Schlusskurs vom Vortag:
$96.31
Offen:
$96.885
24-Stunden-Volumen:
2.01M
Relative Volume:
2.36
Marktkapitalisierung:
$23.13B
Einnahmen:
$3.13B
Nettoeinkommen (Verlust:
$-381.72M
KGV:
-59.98
EPS:
-1.6042
Netto-Cashflow:
$-2.15B
1W Leistung:
-0.54%
1M Leistung:
-13.63%
6M Leistung:
-3.07%
1J Leistung:
-14.48%
1-Tages-Spanne:
$96.04
$97.84
1-Wochen-Bereich:
$95.34
$100.84
52-Wochen-Spanne:
$81.20
$129.27
Biontech Se Adr Stock (BNTX) Company Profile
Vergleichen Sie BNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
96.22 | 23.15B | 3.13B | -381.72M | -2.15B | -1.6042 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
Swedbank AB Makes New $3.42 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Lingohr Asset Management GmbH Sells 36,209 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Rep. Val T. Hoyle Sells BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares - MarketBeat
Baader Bank Aktiengesellschaft Grows Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Benzinga
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Ariva
BioNTech (NASDAQ:BNTX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Fred Alger Management LLC Sells 403,447 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Millennium Management LLC Increases Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Amundi Sells 12,676 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Baird Financial Group Inc. Sells 6,141 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths - One News Page
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):